II

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
수요일, 11월 8, 2023

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Vetter’s European Clinical Site Receives Permanent Manufacturer’s Authorization

Retrieved on: 
목요일, 11월 9, 2023

Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria .

Key Points: 
  • Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria .
  • Operational for nearly two years, the responsible national regulatory authority, the Austrian Agency for Health and Food Safety (AGES) again inspected the site for issuance of a permanent Manufacturer’s Authorization.
  • View the full release here: https://www.businesswire.com/news/home/20231109837386/en/
    High quality standards in aseptic production at Vetter’s clinical site in Vorarlberg, Austria.
  • © Vetter Pharma International GmbH: High quality standards in aseptic production at Vetter’s clinical site in Vorarlberg, Austria.

Global Graves' Disease Drug Pipeline Research Report 2023: Comprehensive Insights About 8+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
목요일, 11월 9, 2023

The "Graves' Disease - Pipeline Insight, 2023" report offers comprehensive insights into the Graves' Disease pipeline landscape, encompassing information on more than 8 companies and over 10 pipeline drugs.

Key Points: 
  • The "Graves' Disease - Pipeline Insight, 2023" report offers comprehensive insights into the Graves' Disease pipeline landscape, encompassing information on more than 8 companies and over 10 pipeline drugs.
  • The report delivers a thorough understanding of the current scenario and growth prospects within the Graves' Disease indication.
  • It furnishes an extensive overview of the Graves' Disease pipeline landscape, including information on the disease itself and treatment guidelines.
  • The assessment section of the report includes a comprehensive commercial assessment of Graves' Disease, as well as a clinical evaluation of the pipeline products currently in development.

Schizoaffective Disorder Drug Pipeline Research Report 2023 Featuring Lyndra Therapeutics, Luye Pharma Group, BioXcel Therapeutics, & Reviva Pharma - ResearchAndMarkets.com

Retrieved on: 
목요일, 11월 9, 2023

The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.

Key Points: 
  • The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.
  • The report delivers a thorough understanding of the current scenario and growth prospects within the Schizoaffective disorder indication.
  • It furnishes an extensive overview of the Schizoaffective disorder pipeline landscape, including information on the disease itself and treatment guidelines.
  • The assessment section of the report includes a comprehensive commercial assessment of Schizoaffective disorder, as well as a clinical evaluation of the pipeline products currently in development.

FIBRA Macquarie México Announces Ordinary and Extraordinary Holders’ Meeting

Retrieved on: 
목요일, 11월 9, 2023

The Call Notice and materials to be presented at the Meeting will be available in FIBRA Macquarie’s website at www.fibramacquarie.com .

Key Points: 
  • The Call Notice and materials to be presented at the Meeting will be available in FIBRA Macquarie’s website at www.fibramacquarie.com .
  • FIBRA Macquarie México (FIBRA Macquarie) (BMV:FIBRAMQ) is a real estate investment trust (fideicomiso de inversión en bienes raíces), or FIBRA, listed on the Mexican Stock Exchange (Bolsa Mexicana de Valores) targeting industrial, retail and office real estate opportunities in Mexico, with a primary focus on stabilized income-producing properties.
  • The obligations of these other Macquarie Group entities do not represent deposits or other liabilities of Macquarie Bank.
  • Macquarie Bank does not guarantee or otherwise provide assurance in respect of the obligations of these other Macquarie Group entities.

Asia-Pacific Data Center Colocation Market Outlook Report 2023-2028 Featuring Key DC Investors - AirTrunk Operating, Digital Realty, Equinix, GDS Services, Keppel, NTT, NEXTDC, & ST Telemedia

Retrieved on: 
수요일, 11월 8, 2023

The development of colocation data centers dominates the data center construction market in APAC in terms of the number of investments.

Key Points: 
  • The development of colocation data centers dominates the data center construction market in APAC in terms of the number of investments.
  • What is the estimated market size in terms of area in the APAC data center colocation market by 2028?
  • What are the key trends in the APAC data center colocation market?
  • How many MW of power capacity is expected to reach the APAC data center colocation market by 2028?

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
월요일, 11월 6, 2023

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

KBW Ranks No. 1 Across Multiple Categories in 2023 Institutional Investor All-America Survey

Retrieved on: 
목요일, 11월 2, 2023

1 firm across multiple categories in the 2023 Institutional Investor (II) All-America survey.

Key Points: 
  • 1 firm across multiple categories in the 2023 Institutional Investor (II) All-America survey.
  • 1 in the II survey, and KBW’s Consumer Finance research team also placed first.
  • 1 in the Financial Institutions Group (FIG) sector, and KBW also had the top-ranked trading/execution team within FIG, in the first such category ever included by II.
  • KBW is the only specialist firm to rank first in any of the sales, trading/execution, and corporate access categories across the II survey, let alone all three.

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
수요일, 11월 1, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2023, along with recent company developments.

Key Points: 
  • Achieved $25.1 million in BRIUMVI net sales for the third quarter 2023; total net product revenue of approximately $48.9 million since launch.
  • Received a permanent J-Code (J2329) for BRIUMVI from the U.S. Centers for Medicare & Medicaid Services (CMS), which became effective July 1, 2023.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $229.2 million as of September 30, 2023.
  • The Company will host a conference call today, November 1, 2023, at 8:30 AM ET, to discuss the Company’s financial results from the third quarter, ended September 30, 2023.

Asia-Pacific Data Center Colocation Market Outlook Report 2023: A $19+ Billion Industry by 2028 - Sustainability Takes Center Stage in Operations - ResearchAndMarkets.com

Retrieved on: 
월요일, 11월 6, 2023

The "Asia-Pacific Data Center Colocation Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Data Center Colocation Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The APAC data center colocation market is expected to reach a value of $19.08 billion by 2028 from $12.01 billion in 2022, growing at a CAGR of 8.02% from 2022-2028
    The APAC data center colocation market stands out as one of the fastest-growing markets globally.
  • What is the estimated market size in terms of area in the APAC data center colocation market by 2028?
  • How many MW of power capacity is expected to reach the APAC data center colocation market by 2028?